1. Lou, Y, Marin-Acevedo, J, Vishnu, P, et al. Hypereosinophilia in a patient with metastatic non-small-cell lung cancer treated with antiprogrammed cell death 1 (anti-PD-1) therapy. Immunotherapy. 2019;11:577-584.
Google Scholar | Crossref | Medline2. Abughanimeh, O, Tahboub, M, Abu Ghanimeh, M. Metastatic lung adenocarcinoma presenting with hypereosinophilia. Cureus. 2018;10:e2866.
Google Scholar | Medline3. Venkatesan, R, Salam, A, Alawin, I, Willis, M. Non-small cell lung cancer and elevated eosinophil count: a case report and literature review. Cancer Treat Commun. 2015;4:55-58.
Google Scholar | Crossref4. Nqwata, L, Wong, M, Mohanlal, R, Lakha, A. Hypereosinophilia as a paraneoplastic phenomenon in non-small cell lung carcinoma. S Afr Respir J. 2015;21:108.
Google Scholar | Crossref5. Borghaei, H, Paz-Ares, L, Horn, L, et al. Nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer. N Engl J Med. 2015;373:1627-1639.
Google Scholar | Crossref | Medline | ISI6. Occhipinti, M, Falcone, R, Onesti, C, Marchetti, P. Hyperprogressive disease and early hypereosinophilia after anti-PD-1 treatment: a case report. Drug Saf Case Rep. 2018;5:12.
Google Scholar | Crossref | Medline7. Failing, J, Dudek, O, Marin Acevedo, J, et al. Biomarkers of hyperprogression and pseudoprogression with immune checkpoint inhibitor therapy. Future Oncol. 2019;15:2645-2656.
Google Scholar | Crossref | Medline8. El-Osta, H, El-Haddad, P, Nabbout, N. Lung carcinoma associated with excessive eosinophilia. J Clin Oncol. 2008;26:3456-3457.
Google Scholar | Crossref | Medline9. Martens, A, Wistuba-Hamprecht, K, Foppen, M, et al. Baseline peripheral blood biomarkers associated with clinical outcome of advanced melanoma patients treated with ipilimumab. Clin Cancer Res. 2016;22:2908-2918.
Google Scholar | Crossref | Medline10. Roufosse, F, Weller, P. Practical approach to the patient with hypereosinophilia. J Allergy Clin Immunol. 2010;126:39-44.
Google Scholar | Crossref | Medline | ISI11. Carretero, R, Sektioglu, I, Garbi, N, Salgado, O, Beckhove, P, Hämmerling, G. Eosinophils orchestrate cancer rejection by normalizing tumor vessels and enhancing infiltration of CD8+ T cells. Nat Immunol. 2015;16:609-617.
Google Scholar | Crossref | Medline | ISI